SEC Form 4 · accession 0000899243-18-002738

Global Blood Therapeutics, Inc. · GBT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Ted W Love

Officer — See Remarks · Director

Period of report

Jan 31, 2018

Accepted (ET)

Feb 2, 2018 · 7:53 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001629137

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Jan 31, 2018	M	35,000	—	A	1,098,413	D
Common Stock^F2	Jan 31, 2018	F	17,353	$57.90	D	1,081,060	D
Common Stock^F1	Feb 1, 2018	M	12,063	—	A	1,093,123	D
Common Stock^F3	Feb 1, 2018	F	5,981	$59.60	D	1,087,142	D
Common Stock	holding	—	—		—	2,500	I	By daughter
Common Stock	holding	—	—		—	2,500	I	By daughter

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Restricted Stock Units^F1,F4	—	Jan 31, 2018	M	35,000	D	—	—	Common Stock	35,000	157,500	D
Restricted Stock Units^F1,F5	—	Feb 1, 2018	M	12,063	D	—	—	Common Stock	12,063	72,375	D
Stock Option (Right to Buy)^F6	$59.60	Feb 1, 2018	A	122,000	A	—	Jan 31, 2028	Common Stock	122,000	122,000	D
Restricted Stock Units^F1,F7	—	Feb 1, 2018	A	78,000	A	—	—	Common Stock	78,000	78,000	D

Explanation of responses

F1Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
F2Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 35,000 shares of Common Stock underlying the Reporting Person's RSUs.
F3Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 12,063 shares of Common Stock underlying the Reporting Person's RSUs.
F4On August 11, 2017, the Reporting Person was granted 262,500 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On January 31, 2018, one of the performance milestones was achieved, resulting in the vesting of 35,000 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
F5On January 17, 2017, the Reporting Person was granted 96,500 RSUs, which vest in equal semi-annual installments over 4 years from February 1, 2017, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
F6The shares underlying the option vest in 16 equal quarterly installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
F7The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

Remarks

Chief Executive Officer and President